Key takeaways
- BPC-157 is a synthetic chain of 15 amino acids reported to come from a gastric-juice protein; GHK-Cu is the copper complex of the tripeptide Gly-His-Lys, first isolated from human plasma in 1973.
- Most BPC-157 research is preclinical: 35 of the 36 studies in a 2025 systematic review. GHK-Cu’s human studies applied it to the skin, and a 2026 review called its clinical evidence “sparse”.
- We found no study that tested the two side by side or together: the eight PubMed records naming both are reviews or a letter (18 Nov 2026).
- US: BPC-157 is covered by HHS’s October 2026 compounding enforcement policy; GHK-Cu is not. FDA lists GHK-Cu, except for injectable routes, among bulk substances under evaluation for compounding, and its advisory committee is due to discuss it before the end of February 2027. Committee votes are advice, not rules.
- Sport: WADA names BPC-157 in class S0, prohibited at all times; GHK-Cu is not named on the 2026 or 2027 List, and WADA says a peptide not named on the List “may still be prohibited”.
01What is BPC-157?
BPC-157 is a pentadecapeptide, a chain of 15 amino acids, made synthetically. FDA staff describe it as reported to be a fragment of a protein, called BPC, that has been found in gastric juice, and write that researchers at the University of Zagreb first synthesised it in the early 1990s. HHS’s 2026 policy appendix gives its sequence as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and its molecular weight as 1,419.54 g/mol, plus the acetate in the salt form.
Most of what is published comes from cells and animals. A 2025 systematic review of musculoskeletal studies found 35 of its 36 included studies were preclinical. The human studies are few and small, most had no control group, and the only randomised data are in conference abstracts. In 2026, FDA staff wrote that its molecular targets “have not been identified” and that its mechanisms of action “remain poorly understood”. More: the BPC-157 research guide and BPC-157 human studies.
02What is GHK-Cu?
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). GHK was first isolated from human plasma in 1973. Without copper, the peptide weighs 340.38 g/mol. In cosmetic ingredient lists it is copper tripeptide-1, and prezatide copper is another name for it. The copper is why its solutions are blue: why is GHK-Cu blue?
Its research is mostly in cells and animals. The human studies applied it to the skin; most were conference posters or pilot reports, known mainly through a 2018 review by GHK’s discoverer. The one PubMed-indexed randomised trial of a skin-care regimen, after laser resurfacing, had 13 completers and found no objective difference from the comparison routine. A 2026 evidence-map review, whose authors declare no conflicts of interest, wrote that its clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”. We found no controlled trial of injected GHK-Cu, published or registered (PubMed and ClinicalTrials.gov, 18 November 2026). More: the GHK-Cu research guide and topical GHK-Cu.
03How do BPC-157 and GHK-Cu differ?
The same questions for both, checked on 18 November 2026. The PubMed counts use one method for both: records naming the compound in the title or abstract, under its common, code and spelling-variant names.
| Question | BPC-157 | GHK-Cu |
|---|---|---|
| What it is | Synthetic peptide of 15 amino acids | Copper(II) complex of a three-amino-acid peptide, Gly-His-Lys |
| Origin | Reported to be a fragment of a protein, BPC, found in gastric juice; first made in Zagreb in the early 1990s | GHK was first isolated from human plasma in 1973 |
| Peptide mass | 1,419.54 g/mol, plus acetate in the salt form (HHS) | 340.38 g/mol without copper (PubChem) |
| Other names | Bepecin, in a 2015 trial registration | Copper tripeptide-1 (cosmetic ingredient name), prezatide copper |
| PubMed records naming it | 234 | 105 |
| Main research models | Rodent models of gut, tendon, ligament, muscle and bone injury; cell studies | Cell and animal studies; skin studies in people |
| Human data | Few studies, most without a control group; randomised data only in conference abstracts | Applied to the skin, mostly in conference posters or pilot reports; one PubMed-indexed randomised trial of a skin-care regimen (13 completers) found no objective difference |
| Independent verdict | 2026 systematic review of the three full papers: certainty of evidence “very low” | 2026 evidence-map review: clinical evidence “remains sparse” |
| ClinicalTrials.gov records | Four; none with posted results | Four apply a product containing it to the skin and one measures blood levels after a patch; none with posted results; none tests injection |
| FDA approval | Not an approved medicine; FDA found it in no approved product in any country it searched | No medicine containing it in Drugs@FDA; as a cosmetic ingredient it needs no FDA approval |
| US compounding | Advisory committee voted for 503A listing (Jul 2026), against FDA staff’s recommendation; covered by HHS’s enforcement-discretion policy (Oct 2026) | Non-injectable routes in Category 1, substances under evaluation (re-added May 2026); injectable form listed among withdrawn Category 2 nominations, citing possible immune reactions; on the agenda of a committee meeting due before the end of February 2027; not in the HHS policy |
| UK | Not a controlled drug; the emc lists no medicine under its names | Not a controlled drug; the emc lists no medicine under its names; an injected product cannot be a cosmetic |
| Australia | Prescription-only (Schedule 4) since 1 June 2024; named in the TGA’s April 2026 advisory on unapproved peptide products | Named in the TGA’s April 2026 advisory among examples of unapproved peptide products, “often supplied in injectable form” |
| WADA | Named in class S0, non-approved substances; prohibited at all times (2026 and 2027 Lists) | Not named on the 2026 or 2027 List; WADA’s 2027 notes say an unnamed peptide “may still be prohibited”; check with your anti-doping body |
The two share almost nothing beyond being short peptides. They differ in size, in origin, in the metal that GHK-Cu carries and BPC-157 does not, and in where their human research sits: rodent injury models and conference abstracts for one, skin studies for the other. A count of records measures attention, not the quality of evidence. How we grade evidence: evidence grades.
04Has any study compared BPC-157 and GHK-Cu?
We found none. On 18 November 2026, PubMed held eight records that name both a GHK or copper-peptide term and a BPC-157 term in the title or abstract. All eight are reviews or a letter: none tested the two side by side, or together, in cells, animals or people. ClinicalTrials.gov lists no study that includes both.
The nearest thing to a joint look is in those reviews. A 2026 scoping review of musculoskeletal research on six peptides, including both, found that 67% of the publications it identified used preclinical animal models, and that human clinical studies were limited to a handful of investigations, most lacking robust controls.
So evidence travels one way only: it attaches to the compound that was studied. Research on one says nothing about the other, and nothing about a mixture. Mixtures sold under brand names are covered on peptide blends. What a given vial holds can only be shown by that lot’s lab report: how to read a COA.
05How do regulators treat BPC-157 and GHK-Cu?
Different histories, which is why “is it legal?” has a different answer for each.
United States. In July 2026 an FDA advisory committee voted in favour of adding BPC-157 to the 503A bulks list, against the recommendation of FDA’s drug centre, and since 28 October 2026 HHS has said it does not intend to act against state-licensed pharmacies, federal facilities and licensed physicians compounding BPC-157 acetate on a patient-specific prescription under ten conditions. The vote is advice, not a rule, and the policy is not binding. GHK-Cu is not in that policy. FDA’s compounding page lists injectable GHK-Cu among substances whose Category 2 nominations were withdrawn, noting that compounded injectable drugs containing it “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities”. FDA’s list of nominated bulk substances places GHK-Cu, except for injectable routes, in Category 1, “bulk drug substances under evaluation”; for those, FDA says it does not intend to take action against compounders that meet the conditions of its guidance. FDA also says the same committee will discuss GHK-Cu, among substances being considered for the 503A bulks list, at a meeting before the end of February 2027; FDA’s page gives no date, and no Federal Register notice had appeared by 18 November 2026. As copper tripeptide-1, GHK-Cu is also a cosmetic ingredient, and FDA says whether a product is a cosmetic or a drug “is determined by a product’s intended use”. Detail: is BPC-157 legal? and peptides and US law.
United Kingdom. Neither is named in Schedule 2 to the Misuse of Drugs Act 1971. The MHRA classifies finished products, not individual substances, so the same peptide can sit in a product treated as a cosmetic and in one treated as a medicine. The UK electronic medicines compendium returned no medicine under either name (searched 18 November 2026). Detail: peptides and UK law.
Australia. BPC-157 has been a Schedule 4, prescription-only substance since 1 June 2024. The TGA’s April 2026 safety advisory names both BPC-157 and GHK-Cu among examples of unapproved peptide products, “often supplied in injectable form”.
Sport. WADA’s Prohibited List names BPC-157 in class S0, non-approved substances, prohibited at all times. It does not name GHK-Cu, in the 2026 List or in the 2027 List that takes effect on 1 January 2027; anti-doping organisations decide how substances the List does not name are treated. WADA’s notes on the 2027 List add that a peptide not specifically named “may still be prohibited”. See peptides and anti-doping.
06What we don’t know about BPC-157 and GHK-Cu
- How the two compare in any model. We found no study that tested them side by side or together.
- Whether animal findings for BPC-157 hold in people. Its only randomised human data are conference abstracts.
- Anything controlled about injected GHK-Cu in people. The human studies applied it to the skin, and FDA says there are “limited data in humans” on compounded injectable GHK-Cu.
- Long-term safety of either in people. We found no published long-term human study of BPC-157 or of injected GHK-Cu.
- What FDA’s advisory committee will say about GHK-Cu, or whether FDA will propose listing either compound. No proposed rule for the 503A bulks list had appeared in the Federal Register by 18 November 2026.
- What a given vial contains. Only an identity result for that lot can show it: mass spectrometry explained.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.